Bullfrog AI Holdings, Inc. (BFRG)
Nasdaq: BFRG · Pharmaceutical Preparations · Gaithersburg, MD · filing with the SEC since 2020
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Report filed | Mar 19, 2026 | Mar 14, 2025 | Mar 29, 2024 | Apr 25, 2023 | · |
| Revenue | 116,670 | · | 65,000 | 10,000 | · |
| Cost of revenue | 94,778 | · | 5,200 | 800 | · |
| Gross profit | 21,892 | · | 59,800 | 9,200 | · |
| Research and development | 1,799,738 | 2,223,265 | 1,432,614 | 609,270 | 25,000 |
| General and administrative | 4,816,790 | 5,013,118 | 3,994,710 | 1,855,731r | 327,329 |
| Total operating expenses | 6,616,528 | 7,236,383 | 5,427,324 | 2,465,001 | 555,362 |
| Operating income | -6,594,636 | -7,236,383 | -5,367,524 | -2,455,801 | -555,362 |
| Interest expense | 5,629 | 18,158 | 79,089 | 347,145 | 40,395 |
| Other income (expense), net | · | · | · | 459 | 9,917 |
| Total non-operating income (expense) | 96,568 | 242,736 | 11,655 | -346,686 | -30,478 |
| Net income | -6,498,068 | -6,993,647 | -5,355,869 | -2,802,487 | -585,840 |
| Net income to common shareholders | -6,498,068 | -7,038,632 | -5,355,869 | · | · |
| Earnings per share, basic | -0.63 | -0.85 | -0.89 | -0.70 | -14.00 |
| Earnings per share, diluted | -0.63 | -0.85 | -0.89 | -0.70 | · |
| Weighted average shares, basic | 10,337,073 | 8,245,353 | 6,049,819 | 4,009,852 | 4,116,336 |
| Weighted average shares, diluted | 10,337,073 | 8,245,353 | 6,049,819 | 4,009,852 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding